Researchers have uncovered a surprising new weapon against an aggressive form of breast cancer: a drug originally developed for pancreatic tumors. The finding offers fresh hope for patients with so called “cold” breast cancers that have resisted standard immunotherapy treatments.
The study focused on a type of breast cancer known as triple negative, which accounts for roughly 15 percent of all breast cancer cases. These tumors are particularly dangerous because they lack the three common receptors that most targeted therapies aim for. The experimental drug, PEP 0101, works by reactivating the immune system’s ability to recognize and attack cancer cells. In laboratory models, the treatment shrank tumors and increased survival rates. Researchers reported that 40 percent of treated mice showed complete tumor regression, a significant improvement over the control group.
How does a pancreatic cancer drug work in the breast? The key lies in a protein called PKC iota, which is overactive in both pancreatic and triple negative breast cancers. This protein helps cancer cells hide from the immune system by creating a “cold” tumor environment, one that immune cells cannot easily infiltrate. PEP 0101 blocks that protein, effectively turning a cold tumor “hot” and making it vulnerable to the body’s own defenses. The drug is already in early stage human trials for pancreatic cancer, and researchers now plan to test it in breast cancer patients as well.
For patients with triple negative breast cancer, current treatment options are limited. Standard chemotherapy remains the frontline approach, but it often comes with harsh side effects and inconsistent results. Immunotherapies like checkpoint inhibitors have helped some patients, but they only work in a minority of cases. PEP 0101 could fill a critical gap by offering a targeted option for the majority of patients whose tumors are considered immunologically “cold.”
What Comes Next
Clinical trials for PEP 0101 in breast cancer are expected to begin within the next year. If successful, the drug could become one of the first treatments to directly target the immune evasion mechanisms of triple negative breast cancer. Researchers are optimistic that this cross cancer discovery could lead to a new class of drugs that reawaken the immune system across multiple tumor types. For now, the study provides a powerful reminder that breakthroughs in one disease can sometimes unlock answers for another.